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IMPORTANCE Few studies are available on the role of maintenance strategies after induction
treatment regimens based on anti–epidermal growth factor receptors, and the optimal
regimen for an anti–epidermal growth factor receptors–basedmaintenance treatment in
patients with RASwild-typemetastatic colorectal cancer is still to be defined.
OBJECTIVE To determine whether maintenance therapy with single-agent panitumumabwas
noninferior to panitumumab plus fluorouracil and leucovorin after a 4-month induction
treatment regimen.
DESIGN,SETTING,ANDPARTICIPANTS Thisopen-label, randomizedphase2noninferiority trialwas
conductedfromJuly7,2015, throughOctober27,2017,atmultiple Italiancenters.PatientswithRAS
wild-type, unresectablemetastatic colorectal adenocarcinomawhohadnot receivedprevious
treatment formetastatic diseasewere eligible. Induction therapy consisted of panitumumab plus
FOLFOX-4(panitumumab,6mg/kg,oxaliplatin,85mg/m2atday1, leucovorincalcium,200mg/m2,
and fluorouracil, 400-mg/m2bolus, followedby600-mg/m2continuous24-hour infusionatdays
1 and2, every 2weeks). Cutoff date for analyseswas July 30, 2018.
INTERVENTIONS Patients were randomized (1:1) to first-line panitumumab plus FOLFOX-4 for
8 cycles followed bymaintenance therapy with panitumumab plus fluorouracil-leucovorin
(arm A) or panitumumab (arm B) until progressive disease, unacceptable toxic effects, or
consent withdrawal. Theminimizationmethod was used to stratify randomization by
previous adjuvant treatment and number of metastatic sites.
MAIN OUTCOMES ANDMEASURES The prespecified primary end point was 10-month
progression-free survival (PFS) analyzed on an intention-to-treat basis with a noninferiority
margin of 1.515 for the upper limit of the 1-sided 90%CI of the hazard ratio (HR) of arm B vs A.
RESULTS Overall,229patients (153male [66.8%];medianage,64years [interquartile range(IQR),
56-70 years])were randomly assigned to armA (n = 117) or armB (n = 112). At amedian follow-up
of18.0months(IQR,13.1-23.3months]),atotalof 169diseaseprogressionordeatheventsoccurred.
ArmBwas inferior (upper limit of 1-sided90%CIof theHR, 1.857). Ten-monthPFSwas59.9%
(95%CI, 51.5%-69.8%) in armAvs49.0%(95%CI, 40.5%-59.4%) in armB (HR, 1.51; 95%CI, 1.11-
2.07;P = .01).Duringmaintenance,armAhadahigherincidenceofgrade3orgreatertreatment-related
adverse events (36 [42.4%]vs 16 [20.3%]) andpanitumumab-related adverse events (27 [31.8%]
vs 13 [16.4%]), comparedwith armB.
CONCLUSIONSANDRELEVANCE In patientswithRASwild-typemetastatic colorectal cancer,
maintenance therapywith single-agent panitumumabwas inferior in termsof PFS comparedwith
panitumumabplus fluorouracil-leucovorin,which slightly increased the treatment toxic effects.
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T he treatment landscape of unresectable metastaticcolorectal cancer (mCRC) has relevantly changed afterthe introduction of biological agents and the develop-
ment of continuum of care strategies. The decision-making
process on the optimal intensity and duration of first-line
treatment in patients with mCRC is based on literature data,
treatment tolerability, patients’ preferences, and costs.1
In pivotal trials of chemotherapydoubletswith orwithout
biological agents,2-5 treatment continuation was scheduled
until progressivediseaseorunacceptable toxic effects.Anega-
tive effect on quality of life of this approach is caused by
oxaliplatin-related cumulative neurotoxicity.6,7 This evidence
paved theway tomaintenance or intermittent strategies in pa-
tientsachievingdiseasecontrolaftercombinationchemotherapy
withorwithoutbevacizumab.6-12Available evidence indicates
thatde-escalating chemotherapy intensity in themaintenance
settingsignificantlyreducesthetoxicityburden,without impair-
ing survival outcomes.6,7 Indeed, fluorouracil and leucovorin–
basedmaintenancetreatmentachievesnoninferiorprogression-
free survival (PFS) compared with no de-escalation,6 while
improving thedurationofdiseasecontrol comparedwith treat-
mentholidays.8,10,12According tocurrentguidelines,1 after a4-
to6-monthinductiontreatmentwithbevacizumabplusdoublet
or triplet13 regimens, bevacizumab plus a fluoropyrimidine is
regarded as the optimalmaintenance regimen.
An anti–epidermal growth factor receptor (EGFR) agent
added to doublet chemotherapy is currently recommended as
a first-line treatment option for patients with RAS wild-type
mCRC.1,14-16 However, the optimal duration of anti-EGFR–
based upfront treatment is still to be defined because, to date,
little evidence-based data are available on the role of
maintenance17,18or intermittent19,20 strategiesafteranti-EGFR–
based induction regimens. We investigated whether, after
4-monthinductiontherapywithpanitumumabplusoxaliplatin-
based doublet chemotherapy, maintenance treatment with
panitumumab was noninferior to panitumumab plus
fluorouracil-leucovorin in patientswithRASwild-typemCRC.
Methods
Study Design and Patient Selection
The VALENTINO study was an open-label, randomized, mul-
ticenter phase 2 noninferiority trial whose participants were
similar tothoseintrials thatestablishedefficacyoffirst-linedou-
bletsplusanti-EGFRs.2-5Thestudyprotocol is found inSupple-
ment 1. Inclusion criteria consistedofhistologically confirmed
colorectal adenocarcinoma; being 18 years or older; Eastern
Cooperative Oncology Group performance status of
0 to 1; no previous treatment for advanced disease; RASwild-
type status locally assessed at local centers according to
European Union–approved standardmethods; disease judged
unresectable by the local multidisciplinary team; measurable
or evaluable lesions according to Response Evaluation
Criteria inSolidTumors(RECIST),version1.1;andadequatebone
marrow, liver,andrenal function.Weexcludedpatientswhohad
received adjuvant oxaliplatin-based chemotherapy and expe-
rienced a relapse during treatment or within 12 months from
treatment completion (or within 6months in the case of adju-
vant fluoropyrimidinemonotherapy). Other exclusion criteria
consistedof clinically relevant cardiovasculardisease, concur-
rent activemalignant neoplasms (except for those disease free
for more than 5 years), or other significant comorbidities that
couldaffectpatients’ outcomes;pregnancy, lactation, or child-
bearingpotential; andnotusingornotwilling tousemedically
approved contraception. Institutional reviewboard and ethics
committee approval was obtained from all participating cen-
ters (eMethods inSupplement2).All thepatientsprovidedwrit-
ten informedconsentbeforeanystudy-relatedprocedures.This
study followed theConsolidated Standards of ReportingTrials
(CONSORT) reporting guideline.
Treatment Plan and Randomization
Datawerecollected fromJuly7,2015, throughOctober27,2017.
Patients were randomly assigned (1:1) to panitumumab plus
FOLFOX-4 (panitumumab, 6 mg/kg [1-hour infusion for the
firstadministration;30-minute infusionthereafter],oxaliplatin,
85mg/m2atday1,andleucovorincalcium,200mg/m2,andfluo-
rouracil,400-mg/m2bolus followedby600-mg/m2continuous
24-hour infusion at days 1 and 2, every 2 weeks), for 8 cycles,
followedbypanitumumabplus fluorouracil-leucovorin (armA)
orpanitumumab(armB).Bothmaintenancetreatmentswerecon-
tinueduntilprogressivedisease,consentwithdrawal,unaccept-
abletoxiceffects,ordeath(eFigure1inSupplement2).Treatment
groupallocationwasperformedwithaminimizationalgorithm
implementinga randomcomponent.Stratification factorswere
numberofmetastaticsites(1vs≥2)andpreviousadjuvanttherapy
(no vs yes).
Study Assessments
Diseaseevaluationwasperformedbymeansofcomputedtomog-
raphyofthethoraxandabdomenormagneticresonanceimaging
scans at screening and every 8weeks thereafter until progres-
sivediseaseordeath.Tumor responsewasclassifiedaccording
to RECIST, version 1.1, as complete response, partial response,
stable disease, or progressive disease. Complete response and
partial response shouldhavebeenconfirmedby2assessments
not less than 4 weeks apart. Patients who discontinued study
Key Points
Question Is maintenance therapy with single-agent panitumumab
noninferior to panitumumab plus fluorouracil and leucovorin after
a 4-month induction treatment with panitumumab plus FOLFOX-4
in patients with previously untreated RASwild-typemetastatic
colorectal cancer?
Findings In this open-label, phase 2 randomized clinical trial of
229 patients, maintenance therapywith single-agent panitumumab
alonewas inferior to panitumumab plus fluorouracil-leucovorin in
terms of 10-month progression-free survival (49.0%vs 59.9%).
Meaning The continuation of single-agent anti–epidermal growth
factor receptor treatment in themaintenance setting will likely
achieve inferior progression-free survival compared with the
continuation of chemotherapy plus an anti–epidermal growth
factor receptor agent in a phase 3 confirmation trial.
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treatmentwithoutprogressivediseasehad tumorassessments
every 8 weeks until progressive disease or study withdrawal.
Treatment safetywasassessedduring the inductionandmain-
tenance phases according to the National Cancer Institute
CommonTerminologyCriteria forAdverseEvents,version4.03.
Theprotocol recommendedpreemptive treatmentof skin rash
withdoxycyclineat thedoseof 100mg/dfor5consecutivedays,
giveneveryothercyclestartingatcycle1,day1.Qualityof lifewas
investigatedthroughtheEuropeanOrganisationforResearchand
TreatmentofCancerQualityofLifeQuestionnairesC30andCR29
andEuroQOL (Europeanquality of life) 5-dimensionquestion-
naires at baseline and every 8weeks until progressive disease.
Quality-of-lifedatawillbeanalyzedwhenmostpatientswillcon-
clude treatmentandwillbepresented inaseparatepublication.
BRAFcodon600mutationswerecentrallyconfirmed,asprevi-
ously described.21
Outcomes
The primary end point was PFS. The aim was to compare 10-
month PFS in the 2 treatment arms. Progression-free survival
wasassessed locally as the interval fromrandomization to first
objective documentation of progressive disease or death
due to any cause, whichever occurred first (censoring at last
follow-up for patients alive andwithout progressive disease).
Secondary endpointswere safety, overall survival, overall re-
sponse rate, disease control rate, duration of response, and
quality of life. Overall survivalwas the interval from random-
ization to death due to any cause (censoring at last follow-up
for patients alive). Overall response rate was defined as the
proportion of patients achieving an objective response (com-
plete or partial), and disease control rate was defined as the
proportion of patients achieving a complete or a partial re-
sponse or stable disease. Duration of responsewas defined as
the interval from first documented response to progressive
disease or death due to any cause, whichever occurred first
(censoring at the date of last follow-up for patients alive and
without progressive disease).
Statistical Analysis
Activityandefficacyanalyseswereperformedfor the intention-
to-treat population (all randomized patients) and for the per
protocol population (includingpatientswith complete or par-
tial response or stable disease after induction who received
≥1maintenance cycle). Safety analyseswereperformed forpa-
tientswho received at least 1 induction cycle. Sample sizewas
calculated taking into account the 10.1-monthmedianPFS re-
portedby thePRIME trial (PanitumumabRandomizedTrial In
Combination With Chemotherapy for Metastatic Colorectal
Cancer toDetermineEfficacy) in thepatient subgroupwithRAS
wild-type tumors.2 A sample of 224 patients, 112 per arm, re-
cruited during a 2-year period would achieve 90% power to
detect 50% PFS in arm A and a maximum difference of 15%
less in arm B (1-sided α = 0.1, with a 15% dropout rate taken
into account). These assumptionswould imply a noninferior-
ity limit equal to 1.515 for the PFS hazard ratio (HR) of arm B
vsA, that is, howmuchA can exceed B,with B still being con-
siderednoninferior toA. Thenull hypothesis for provingnon-
inferiority was HR (B vs A) of at least 1.515 (B is inferior to A);
the alternative hypothesis, was HR (B vs A) of less than 1.515
(B is not inferior to A). The null hypothesis would have been
rejected in favor of the alternative if the upper limit of the
1-sided 90% CI for HR, estimated in a Cox proportional haz-
ards regressionmodel stratified byprior adjuvant therapy (no
or yes) and number of disease sites (1 or ≥2), was lower than
1.515. Overall survival and PFS curveswere estimated in the 2
treatment arms by the Kaplan-Meier method and compared
using the log-rank test. Binomial 2-sided 95%CIswere calcu-
lated for overall response rate and disease control rate. The
Mantel-Haenszel methodwas applied to estimate the pooled
odds ratio (OR) of response in armB vs A across the strata de-
terminedaccording to thestratification factorsandtestedusing
the Cochran Mantel-Haenszel test. Duration of response and
median duration of response were estimated by the Kaplan-
Meier method and compared using the log-rank test. Sub-
group analyses were performed by estimating Kaplan-Meier
curves according to treatment arm in each subgroup; Cox
proportionalhazards regressionmodelswith interaction treat-
ment × subgroupwere fitted to estimateHRsandcorrespond-
ing 95% CIs. Median follow-up was calculated by the reverse
Kaplan-Meier approach. A stratified univariable Cox propor-
tional hazards regression model was fitted to estimate the
HR of arm B vs A for overall survival.
All tests were 2 sided at α = .05, with the exception of the
1-sidedtestofnoninferiorityforPFS.Theanalyseswereperformed
usingSASsoftware,version9.1(SASInstitute,Inc),andRsoftware,
version 3.4.1 (R Foundation for Statistical Computing).
Results
Patient Populations
FromJuly 7, 2015, throughOctober 27, 2017, 229patients (153
male [66.8%]and76 female [33.2%];medianage, 64years [in-
terquartile range (IQR), 56-70years])were randomized to arm
A (n = 117) or arm B (n = 112). Patients’ demographic and dis-
ease characteristicswerewell balanced in both arms (eTable 1
inSupplement2). Threepatientswere randomizedbutdidnot
receive study treatment. Themain reasons for treatment dis-
continuation were progressive disease in 135 (59.7%), resec-
tion for metastases in 32 (14.2%), adverse events in 3 (1.3%),
deaths in 7 (3.1%), andpatient or investigatordecisionorother
reasons in 21 (9.3%) (Figure 1).
Efficacy
The cutoff date for analyses was July 30, 2018. The median
treatmentdurationwas 7.4months (IQR, 4.3-12.4months) for
the overall population, 8.4 months (IQR, 4.7-14.0 months)
for arm A, and 7.0 months (IQR, 4.0-10.5 months) for arm B.
Progression-free survival events occurred in 169 (including 15
deaths in the absence of progression), consisting of 83 in arm
A (including 6 deaths) and 86 in arm B (including 9 deaths);
median follow-up was 18.0 months (IQR, 13.1-23.3 months).
The null hypothesis of inferiority of armB vs armA could
not be rejected because the upper limit of the 1-sided 90% CI
of the HR was 1.857 and exceeded the 1.515 noninferiority
boundary. In armA, 10-month PFSwas 59.9% (95%CI 51.5%-
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69.8%) and median PFS was 12.0 months (95% CI, 10.4-14.5
months). In comparison, 10-month PFS was 49.0% (95% CI,
40.5%-59.4%) andmedian PFS was 9.9months (95% CI, 8.4-
11.0months) in armB (log-rank test, P = .006) (Figure 2A and
eTable 2 in Supplement 2). TheHRof armBvs armA from the
univariableCoxproportional hazards regressionmodel strati-
fiedbyprior adjuvant therapyandnumberofdisease siteswas
1.51 (95% CI, 1.11-2.07; P = .009) (eTable 2 in Supplement 2).
The overall number of deathswas 74, including 40 in arm
Aand 34 in armB.Overall survival at themedian follow-up of
18 months was 66.4% (95% CI, 57.1%-77.2%) in arm A and
62.4% (95%CI, 52.3%-74.4%) in armB (HR,1.13; 95%CI, 0.71-
1.81; P = .60) (Figure 2B and eTable 2 in Supplement 2).
Therewasnosignificantdifferencebetweenarms in terms
of overall response rate and disease control rate (eTable 2 in
Supplement 2). Overall response rate was 66.7% (95% CI,
57.4%-75.1%) inarmAand67.0%(95%CI, 57.4%-75.6%) inarm
B; the pooled OR for overall response rate in arm B vs A was
1.07 (95%CI,0.61-1.86) (P = .82).Diseasecontrol ratewas82.9%
(95% CI, 74.8%-89.2%) in arm A and 83.9% (95% CI, 75.8%-
90.2%) in arm B; the pooled OR for disease control rate in
arm B vs A was 1.06 (95% CI, 0.52-2.15; P = .87). In the 153
patients achieving RECIST response, median duration of
response was 10.9 months (IQR, 5.8-21.0 months) in arm A
and9.0months (IQR, 5.9-14.7months) in armB (P = .16) (eFig-
ure 2 in Supplement 2).
The forestplots showing treatmentHRand95%CIaccord-
ing to stratification factors and other prognostic variables are
shown inFigure 3 (for PFS) and eFigure 3 in Supplement 2 (for
overall survival). Theperprotocolpopulation included 164pa-
tients, 85 in armAand79 in armB.Median follow-upwas 17.9
months (IQR, 13.1-23.3 months). In arm A, 10-month PFS was
70.3%(95%CI61.2%-80.8%)andmedianPFSwas 14.1months
(95%CI, 11.3-17.2months). In armB, 10-monthPFSwas 59.0%
(95%CI, 49.0%-71.0%);medianPFSwas 10.8months (95%CI,
9.9-13.3months); andHRwas 1.50 (95%CI, 1.03-2.19;P = .04)
(eFigure4A inSupplement2).Foroverall survival,HRwas0.95
(95% CI, 0.50-1.82; P = .88) (eFigure 4B in Supplement 2).
Safety
Dosedelaysandreductionsare reported ineMethods inSupple-
ment2. In thesafetypopulationof226patients, adverseevents
of at least grade 3 occurred in 52 patients (31.7%), including
36 (42.4%) in arm A and 16 (20.3%) in arm B. In arm A, an
Figure 1. Consort Diagram of the Study
117 Randomized to arm A
(panitumumab plus FU/LV)
115 Received induction therapy
(8 cycles panitumumab plus FOLFOX4)
85 Received panitumumab plus
FU/LV maintenance
17 Treatment ongoing
117 Included in the intention-to-treat
population
111 Received induction therapy
(8 cycles panitumumab plus FOLFOX4)
112 Randomized to arm B (panitumumab)
2 Did not receive induction 1 Did not receive induction
229 Patients treated
29 Italian centers (July 7, 2015-October 27, 2017)
30 Did not receive maintenance 
14 Disease progression 
3 Death
5 Surgery
1 Adverse event 
2 Other
5 Patient's decision
0 Local treatment
68 Discontinued treatment
53 Disease progression
2 Patient's decision
8 Surgery
1 Adverse event
4 Other
79 Received panitumumab maintenance
11 Treatment ongoing
112 Included in the intention-to-treat
population
32 Did not receive maintenance 
19 Disease progression 
4 Death
4 Surgery
0 Adverse event 
2 Other
1 Patient's decision
2 Local treatment
68 Discontinued treatment
49 Disease progression
0 Patient's decision
15 Surgery
1 Adverse event
3 Other
229 Randomized
FOLFOX4 indicates panitumumab,
6mg/kg (1-hour infusion for the first
administration, 30-minute infusion
thereafter), oxaliplatin, 85mg/m2
at day 1, leucovorin calcium,
200mg/m2, and fluorouracil,
400-mg/m2 bolus, followed by
600-mg/m2 continuous 24-hour
infusion at days 1 and 2, every
2 weeks. FU indicates fluorouracil;
LV, leucovorin.
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increased incidence of diarrhea (any grade, 21 [24.7%] vs 8
[10.1%];grade≥3,4 [4.7%]vs1 [1.3%])andstomatitis (anygrade,
28 [32.9%] vs 6 [7.6%]; grade ≥3, 6 [7.1%] vs 1 [1.3%]) occurred
compared with arm B. Panitumumab-related toxic effects
(mainly skin rash, paronychia, hypomagnesemia, and con-
junctivitis)were reported inmost patients, although the rates
werehigher in armAvsB (anygrade, 65 [76.5%]vs 33 [41.8%];
grade ≥3, 27 [31.8%] vs 13 [16.5%]). Patients experienced neu-
rotoxic effects of any grade in 84 cases (37.2%) and of grade 3
or higher in 7 (3.1%). Notably, 3 patients died of sepsis during
the induction phase (eTable 2 in Supplement 2).
Discussion
The rationaleof amaintenance strategywithanti-EGFRs inab-
sence of the fluoropyrimidine backbone is supported by the
single-agent efficacy of such drugs in patients with molecu-
larly selectedmCRC. TheMACRO-2 trial17 suggested the non-
inferiority in terms of 9-month PFS of maintenance treat-
ment with cetuximab alone compared with continuation of
modifiedFOLFOX-6plus cetuximab, even though the trialwas
conducted in patients with KRAS exon 2 wild-type mCRC.
Such limitation and the small sample size highlighted the
need for larger studies restricted toRASwild-typemCRC. The
VALENTINOphase2studyprospectivelyenrolledpatientswith
RASwild-type mCRC and showed that maintenance therapy
with single-agent panitumumab was inferior in terms of PFS
compared with panitumumab plus fluorouracil-leucovorin,
which slightly increased the treatment toxicity. Even if we
adopted a large noninferiority margin as high as 1.515, this
reinforces the clear PFS inferiority of single-agent panitu-
mumabasmaintenance treatment, so that a subsequentphase
3 trial would have an extremely low probability of meeting
a primary end point of noninferiority.
The PFS benefit of adding fluorouracil-leucovorin to pani-
tumumab in themaintenancesettingdidnotdifferaccording to
main subgroups, including those with poorer prognosis and
primary resistance toanti-EGFRagents, suchas right-sidedpri-
marytumorsorBRAF-mutatedones.16,22Theprevalenceofright-
sided tumorswas only 17%, and that ofBRAF-mutated tumors
wasonly4%,therefore lowerthanexpectedintheRASwild-type
population, showing an increased refinement of patients’
selection in the clinical practice. Even if the absence of a
panitumumab-free armdid not allowus to performpredictive
analyses,PFS in these2subgroupswasparticularlypoor inarm
B (Figure 2). The clinical importance of further investigating
anti-EGFR–based maintenance in these patient subgroups is
modest because anti-EGFR agents are not commonly used in
the upfront treatment ofmost patientswithBRAF-mutated or
right-sided (RASwild-type)mCRC.1,14
Our results are biologically sound for at least 2 reasons.
First, several patients with RAS wild-type mCRC are primar-
ily resistant toEGFR inhibitionowing to thepresenceofEGFR-
independent oncogenicdrivers other thanRAS andBRAFmu-
tations, specific gene expressionprofiles, andoverexpression
of specificmicroRNAs such asmicroRNA 31-3p.16,22-24 There-
fore, in this clinically and biologically heterogeneous patient
population, single-agent anti-EGFRs may represent a subop-
timal maintenance treatment option compared with chemo-
therapy continuation. Second, in tumorswith initial sensitiv-
ity to EGFR inhibition, acquired resistancemay be delayed by
thesynergisticeffectof thecombinedchemotherapeuticagent.
In our study, the duration of response curves were similar in
both arms to 6 months but progressively diverged over time
(eFigure 2 in Supplement 2), suggesting the presence of a pa-
tient subgroup achieving long-term response with the com-
bination of panitumumab and fluorouracil-leucovorin.
Maintenance treatment with single-agent panitumumab
had less toxic effects, although the safety profile was clearly
Figure 2. Kaplan-Meier Curves for Progression-Free Survival (PFS) andOverall Survival According to Treatment Arm
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Data are shown in the intention-to-treat population at the date of first data
cutoff (July 30, 2018). Ten-month PFS was 59.9% (95% CI, 51.5%-69.8%) vs
49.0% (95% CI, 40.5%-59.4%) in arm A vs arm B. The hazard ratio (HR) of arm
B vs arm Awas 1.51 (95% CI, 1.11-2.07; P = .009). Overall survival at themedian
follow-up of 18months was 66.4% (95% CI, 57.1%-77.2%) vs 62.4%
(52.3%-74.4%) in arm A vs arm B (HR, 1.13; 95% CI, 0.71-1.81; P = .60).
FU indicates fluorouracil; LV, leucovorin.
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manageable inbothtreatmentarms.Indeed,preemptivetherapy
for toxic effects on the skinwas recommended by our study to
decrease the incidence of skin rash of grade 3 or higher accord-
ingtotheliterature.24Theincidenceof26.5%(60patients) inthe
VALENTINOstudyfavorablycompareswith37%reported inthe
PRIME trial.2Most importantly, the extremely low incidenceof
grade 3 neurotoxic effects (3.1%) is in linewith other academic
trials scheduling early discontinuationof oxaliplatin treatment
after a preplannednumber of cycles.8,13,19,25
Amongpostinduction strategies aimedat improvingqual-
ity of life, intermittent treatments have been investigated by
dedicated clinical trials. These strategies may have a remark-
able clinical value in patients with low disease burden and in
those who achieve the rapid and deep tumor responses typi-
cally associated with anti-EGFR–based first-line regimens.26
Among the few available evidences for such strategies in the
era of biological agents,19,20 the randomized noncompara-
tive phase 2 COIN-B study19 was conducted in patients with
KRASexon2wild-typemCRCandshowed that treatmentholi-
days followed by reinduction therapy at progressive disease
andmaintenance therapywith cetuximab alonemay achieve
noninferior failure-freesurvival comparedwithhistoricaldata.
However, in the comparative analysis, a treatment break was
associatedwith inferioroverall survival andpostinductionPFS
compared with maintenance therapy with cetuximab.
Limitations
Our study has some limitations. First, the control arm (pani-
tumumab plus fluorouracil-leucovorin) could have been re-
gardedasexperimental. Indeed,discontinuingoxaliplatintreat-
ment after a preplanned number of cycles has improved
tolerability,withclearlyacceptable lossofefficacy.6,7Theavail-
able evidenceonanti-EGFR–based treatments is limited to the
randomized phase 2 SAPPHIRE study,18 showing similar
9-month PFS when de-escalating to panitumumab plus fluo-
rouracil-leucovorin or continuing panitumumab plus modi-
fiedFOLFOX-6 therapy. Second, the lackof a single-agent fluo-
rouracil-leucovorin armhampered the chanceof assessing the
specific effect of continuing panitumumab in the mainte-
nancesetting,as investigatedbytheongoingrandomizedphase
2 PanaMa study.27 Third, in our study, randomization was
plannedbefore starting induction treatment, andpatientswho
Figure 3. Forest Plots of Progression-Free Survival by Patient SubgroupsWithin the Intention-to-Treat Population
0 3 72 4 5 6
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Plus FU/LV
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Panitumumab
Plus FU/LV Panitumumab
Median PFS (95% CI), mo
Panitumumab
Plus FU/LV PanitumumabCharacteristic
Sex
HR
(95% CI)
27/38 30/38 10.72 (8.59-18.40) 10.00 (7.17-13.20)Female 1.44 (0.85-2.43)
56/79 56/74 12.07 (10.43-16.00) 9.74 (8.65-12.60)Male 1.58 (1.08-2.31)
Age, y
45/59 45/64 11.02 (9.47-14.20) 10.59 (8.26-13.30)<65 1.21 (0.79-1.84)
38/58 41/48 13.03 (10.43-22.00) 9.13 (8.39-12.60)≥65 2.01 (1.28-3.15)
ECOG performance status
57/84 60/81 13.13 (10.46-16.00) 10.07 (8.85-13.20)0 1.49 (1.03-2.15)
26/33 26/31 9.84 (7.20-16.20) 7.40 (4.08-12.40)1 1.80 (1.03-3.14)
Prior adjuvant treatment
9/17 16/19 24.34 (22.93-NA) 8.85 (4.08-15.40)Yes 4.47 (1.93-10.32)
74/100 70/93 10.53 (9.47-13.10) 9.93 (8.65-11.60)No 1.26 (0.91-1.76)
Primary tumor resected
49/73 55/72 13.03 (11.02-17.20) 10.03 (8.29-12.60)Yes 1.86 (1.25-2.77)
34/44 31/40 10.34 (7.34-14.20) 9.38 (8.26-13.30)No 1.13 (0.69-1.84)
Liver metastases only
28/42 27/39 12.07 (9.47-16.90) 10.69 (9.74-14.70)Yes 1.13 (0.67-1.92)
55/75 59/73 11.45 (9.51-15.40) 8.72 (7.40-12.40)No 1.85 (1.26-2.70)
Synchronous metastases
68/94 66/83 10.53 (9.47-13.10) 9.38 (8.29-10.80)Yes 1.48 (1.05-2.09)
15/23 20/29 22.01 (14.11-NA) 11.58 (7.83-NA)No 1.91 (0.97-3.77)
Number of metastatic sites
40/62 48/64 14.14 (11.28-22.00) 10.59 (8.75-13.20)1 1.67 (1.08-2.57)
43/55 40/48 9.51 (7.96-13.00) 8.72 (6.45-12.60)≥2 1.50 (0.97-2.32)
Primary tumor site
15/19 19/21 8.63 (5.86-NA) 6.97 (4.51-8.88)Right colon 2.10 (1.06-4.16)
68/98 67/91 12.86 (10.53-15.20) 10.69 (9.74-13.13)Left colon or rectum 1.45 (1.03-2.05)
BRAF status
31/113 79/103 12.04 (10.39-14.60) 10.07 (8.75-11.70)Wild-type 1.50 (1.09-2.06)
2/4 7/9 8.42 (2.73-NA) 5.59 (1.78-NA)Multated 1.14 (0.22-5.92)
All patients 83/117 86/112 12.00 (10.40-14.50) 9.90 (8.40-11.00) 1.51 (1.11-2.07)
ECOGindicatesEasternCooperativeOncologyGroup;FU, fluorouracil;HR,hazard ratio; LV, leucovorin.Dashed line indicatespredefinednoninferiorityboundary (HR, 1.515).
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couldnotproceedto the randomlyassignedmaintenancestrat-
egy were included in the intention-to-treat analysis. How-
ever, the results obtained in the per protocol and intention-
to-treat populations were highly consistent. Finally, the
reintroductionofFOLFOX-4pluspanitumumabafter progres-
sive disease during the maintenance phase was not sched-
uled by our study. Indeed, the negative data on continuation
of anti-EGFR–based treatment beyond progression are con-
sistent with the well-described emergence of tumor clones
with genomic resistance to EGFR inhibition.28,29
Conclusions
Despite the noninferiority design and the sample size, this
study clearly demonstrates the inferiority of maintenance
treatment with single-agent panitumumab compared with
panitumumab plus fluorouracil-leucovorin. Even if panitu-
mumab plus fluorouracil-leucovorin were to be regarded as
the optimal maintenance strategy after an oxaliplatin-based
induction treatment, this conclusion cannot be generalized
for a combination chemotherapy including irinotecan,
because the issue of cumulative toxic effects is less clini-
cally significant. Most important, even if the VALENTINO
study planned the discontinuation of oxaliplatin treatment
after a fixed 4-month induction, the clinical decision
making on treatment de-escalation and its timing should
be dynamically managed by physicians by taking into
account several factors, such as available evidence, patient
preference, baseline patient- and disease-related character-
istics, specific drug toxicities, and response to induction
treatment.
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